BRAINVECTIS
Brainvectis is focused on the development of treatments that focus on neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. It researches about the restoration of brain cholesterol metabolism by increasing CYP46A1 in the patients’ brains. Brainvectis was founded by Nathalie Cartier Lacave in 2015. It is based in Fontenay-aux-Roses, France.
BRAINVECTIS
Social Links:
Industry:
Medical Medical Device Therapeutics
Founded:
2015-01-01
Address:
Fontenay-aux-roses, Ile-de-France, France
Country:
France
Website Url:
http://www.brainvectis.com
Total Employee:
1+
Status:
Active
Total Funding:
1000 K EUR
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Pound Sterling Japanese Yen AWS Global Accelerator
Current Employees Featured
Founder
Official Site Inspections
http://www.brainvectis.com Semrush global rank: 5.13 M Semrush visits lastest month: 729
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Brainvectis"
BrainVectis Company Profile 2024: Valuation, Investors ... - PitchBook
BrainVectis General Information Description. Developer of a gene therapy intended for neuro-degenerative diseases. The company develops gene therapy treatments for Alzheimer's and …See details»
Brainvectis Company Profile - Office Locations, Competitors ... - Craft
BrainVectis is a company that provides gene therapy treatments for neurodegenerative diseases by restoring brain cholesterol metabolism. It develops therapeutics targeting the cholesterol …See details»
BrainVectis SAS - Drug pipelines, Patents, Clinical trials - Synapse
Explore BrainVectis SAS with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 5 news, Disease Domain:Nervous System Diseases, Endocrinology and Metabolic …See details»
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for ...
Apr 22, 2020 Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that it has acquired …See details»
BrainVectis - Products, Competitors, Financials, Employees ...
BrainVectis develops gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Dr. Nathalie Cartier-Lacave …See details»
BrainVectis - euroquity.com
About your organization Numerous data in animal models and in human patients have shown the role of impaired cholesterol metabolism in neurodegenerative diseases, particularly in …See details»
BrainVectis - LinkedIn
Based on work carried out by Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), …See details»
Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc.
Brainvectis is a leading biotechnology company that specializes in developing innovative gene therapies for neurological. Menu. Search for Clinical Trials. Autoimmunity. Cancers. …See details»
Brainvectis - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 13, 2016: Series A - …See details»
Brain Vectis - Company Profile - Tracxn
Dec 22, 2024 Brain Vectis - Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease. Raised a total funding of $1.1M over 1 round from 1 investor. Founded …See details»
As Askbio acquires Brainvectis, Erganeo’s first start-up flies the nest.
May 26, 2020 On 17 April, just over four and a half years after it was founded, Brainvectis, a start-up supported by Erganeo specialising in neurodegenerative disease treatments, was …See details»
Brainvectis - Contacts, Employees, Board Members, Advisors
Treat neurodegenerative diseases by restoring brain cholesterol metabolismSee details»
AskBio acquires BrainVectis, a French gene therapy company …
Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for neurodegenerative disorders. Founded in 2015, …See details»
Brainvectis Company Information - Funding, Investors, and More
The company Brainvectis has raised a total of $1.2m in funding over 1 rounds. Key Insights: Series A: $1.2m; 2016. Brainvectis Series A round, September 2016 $1.2m. Discover Iwoca. …See details»
AskBio Acquires BrainVectis - American Pharmaceutical Review
Apr 23, 2020 BrainVectis was founded by award-winning physician and gene therapy pioneer Nathalie Cartier-Lacave, M.D., with early funding and support from INSERM, Sorbonne …See details»
Asklepios BioPharmaceutical acquires Brainvectis - 2020-04-22 ...
Apr 22, 2020 Asklepios BioPharmaceutical acquires Brainvectis on 2020-04-22 for an undisclosed amount. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
AskBio Takes Over BrainVectis to Treat Alzheimer’s and Huntington’s
Apr 28, 2020 The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy …See details»
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for ...
Apr 24, 2020 BrainVectis adds Huntington’s disease gene therapy candidate to AskBio’s program. Research Triangle Park, N.C. and Paris, France – Asklepios BioPharmaceutical, Inc. …See details»
BrainVectis receives funding to support gene therapy for …
Sep 13, 2016 BrainVectis receives funding to support gene therapy for Huntington’s and Alzheimer’s disease. Parisian-based BrainVectis, a spin-off of Inserm, has received €1m in …See details»